Sector News

Takeda takes full control of drug for rare epilepsies

March 6, 2021
Life sciences

Takeda, the world’s largest developer of rare disease drugs, said Tuesday that it has reclaimed full rights to an experimental medicine being tested against uncommon forms of epilepsy. The deal inked with New York-based Ovid Therapeutics carries an almost $200 million upfront payment and could be worth as much as $856 million provided the medicine, known as soticlestat, hits certain milestones.

Soticlestat was discovered at Takeda’s research center in Shonan, Japan, and is supposed to block an enzyme expressed in parts of the brain responsible for learning and memory. In 2017, Takeda teamed up with Ovid, a neuroscience-focused biotech, to develop and commercialize the drug for rare epilepsies. The companies then expanded their collaboration the following year.

Now, Takeda is working to secure all rights to its drug. Terms of the new deal, which is expected to close this month, have Takeda taking sole responsibility of the drug, while Ovid is absolved of any financial obligations under the original agreement. Soticlestat is currently in mid-stage testing, where researchers are evaluating it across several developmental and epileptic brain diseases, including Dravet syndrome and Lennox-Gastaut syndrome. READ MORE

By Jacob Bell

Source: biopharmadive.com

comments closed

Related News

March 24, 2024

Johnson Matthey to sell its Medical Devices business for $700 million

Life sciences

Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.

March 24, 2024

Lonza acquires biologics manufacturing plant in California from Roche

Life sciences

Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.

March 24, 2024

Roquette to acquire IFF Pharma Solutions to boost global excipient presence

Life sciences

Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.

How can we help you?

We're easy to reach